Table 1 Baseline characteristics in patients with HFEM status
Placebo (n = 592) | GMB 120 mg (n = 294) | GMB 240 mg (n = 290) | |
|---|---|---|---|
Age, years, mean (SD) | 41.5 (11.3) | 40.6 (11.4) | 40.1 (11.5) |
Female, n (%) | 518 (87.5) | 249 (84.7) | 251 (86.6) |
Years since migraine diagnosis, mean (SD) | 20.3 (12.3) | 20.7 (12.1) | 19.5 (11.9) |
Number of migraine headache days, mean (SD) | 10.9 (2.0) | 10.9 (2.0) | 10.7 (2.0) |
MSQ v2.1 Role Function Restrictive (SD) | 49.9 (15.0) # | 49.5 (15.2) | 48.8 (16.7)## |
MIDAS total score, mean (SD) | 36.9 (31.5) # | 35.3 (30.2) | 37.2 (29.7)## |